Medtronic and Viz.ai have announced a new partnership aimed at speeding up the implementation of Viz.ai’s AI solution for detecting suspected large vessel occlusion (LVO) strokes.
The solution identifies LVO strokes and immediately notifies the necessary specialists. It is connected directly to a facility’s CT scanners and automatically sends images of the suspected LVO stroke to a radiologist’s smart phone.
Through this new partnership, Medtronic will now distribute Viz.ai’s solution. Medtronic’s own Solitaire Platinum revascularization device is also aimed at treating LVO stroke patients.
“Medtronic is an innovative company focused on therapies that extend life and restore health,” Chris Mansi, MD, co-founder and CEO of Viz.ai, said in a prepared statement. “As the largest medical device company in the world, Medtronic is an ideal partner to help physicians access Viz.ai’s cutting-edge technology to ensure as many patients get the care they need as quickly as possible.”
“Viz.ai allows clinicians to receive an alert for suspected Large Vessel Occlusions and the corresponding visual data,” Elad Levy, MD, chairman in the department of neurosurgery with the University at Buffalo’s Jacobs School of Medicine and Biomedical Sciences, said in the same statement. “The combination of AI powered alerts, mobile image viewing, and HIPAA compliant communication facilitates synchronization of stroke care with great potential to impactfully reduce door-to-needle time and help an increased number of patients.”
Michael has more than 16 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.